1. Home
  2. OPT vs CPSS Comparison

OPT vs CPSS Comparison

Compare OPT & CPSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OPT
  • CPSS
  • Stock Information
  • Founded
  • OPT 1984
  • CPSS 1991
  • Country
  • OPT Australia
  • CPSS United States
  • Employees
  • OPT N/A
  • CPSS N/A
  • Industry
  • OPT Biotechnology: Biological Products (No Diagnostic Substances)
  • CPSS Finance: Consumer Services
  • Sector
  • OPT Health Care
  • CPSS Finance
  • Exchange
  • OPT Nasdaq
  • CPSS Nasdaq
  • Market Cap
  • OPT 201.5M
  • CPSS 210.2M
  • IPO Year
  • OPT 2020
  • CPSS 1992
  • Fundamental
  • Price
  • OPT $3.24
  • CPSS $9.70
  • Analyst Decision
  • OPT Strong Buy
  • CPSS
  • Analyst Count
  • OPT 2
  • CPSS 0
  • Target Price
  • OPT $14.00
  • CPSS N/A
  • AVG Volume (30 Days)
  • OPT 10.8K
  • CPSS 53.5K
  • Earning Date
  • OPT 08-30-2024
  • CPSS 11-07-2024
  • Dividend Yield
  • OPT N/A
  • CPSS N/A
  • EPS Growth
  • OPT N/A
  • CPSS N/A
  • EPS
  • OPT N/A
  • CPSS 1.09
  • Revenue
  • OPT $261,859.00
  • CPSS $188,418,000.00
  • Revenue This Year
  • OPT N/A
  • CPSS N/A
  • Revenue Next Year
  • OPT $55,563.16
  • CPSS $27.70
  • P/E Ratio
  • OPT N/A
  • CPSS $8.78
  • Revenue Growth
  • OPT N/A
  • CPSS N/A
  • 52 Week Low
  • OPT $1.60
  • CPSS $7.03
  • 52 Week High
  • OPT $4.40
  • CPSS $12.04
  • Technical
  • Relative Strength Index (RSI)
  • OPT 70.30
  • CPSS 59.67
  • Support Level
  • OPT $2.84
  • CPSS $9.21
  • Resistance Level
  • OPT $3.19
  • CPSS $9.76
  • Average True Range (ATR)
  • OPT 0.14
  • CPSS 0.39
  • MACD
  • OPT 0.01
  • CPSS 0.16
  • Stochastic Oscillator
  • OPT 100.00
  • CPSS 75.79

About OPT Opthea Limited

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.

About CPSS Consumer Portfolio Services Inc.

Consumer Portfolio Services Inc is a U.S.-based company operating in the specialty finance sector. Its business is to purchase and service retail automobile contracts originated by franchised automobile dealers and, to a lesser extent, by select independent dealers in the United States in the sale of new and used automobiles, light trucks, and passenger vans. Through its automobile contract purchases, the company provides indirect financing to the customers of dealers having limited credit histories, low incomes, or past credit problems, who it refers to as sub-prime customers. It serves as an alternative source of financing for dealers, facilitating sales to customers.

Share on Social Networks: